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Abstract
Background: Antisocial personality disorder (ASPD), although associated with very significant health and social
burden, is an under-researched mental disorder for which clinically effective and cost-effective treatment methods are
urgently needed. No intervention has been established for prevention or as the treatment of choice for this disorder.
Mentalization-based treatment (MBT) is a psychotherapeutic treatment that has shown some promising preliminary
results for reducing personality disorder symptomatology by specifically targeting the ability to recognize and
understand the mental states of oneself and others, an ability that is compromised in people with ASPD. This paper
describes the protocol of a multi-site RCT designed to test the effectiveness and cost-effectiveness of MBT for reducing
aggression and alleviating the wider symptoms of ASPD in male offenders subject to probation supervision who fulfil
diagnostic criteria for ASPD.
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Methods: Three hundred and two participants recruited from a pool of offenders subject to statutory supervision by
the National Probation Service at 13 sites across the UK will be randomized on a 1:1 basis to 12months of probation
plus MBT or standard probation as usual, with follow-up to 24months post-randomization. The primary outcome is
frequency of aggressive antisocial behaviour as assessed by the Overt Aggression Scale – Modified. Secondary
outcomes include violence, offending rates, alcohol use, drug use, mental health status, quality of life, and total service
use costs. Data will be gathered from police and criminal justice databases, NHS record linkage, and interviews and
self-report measures administered to participants. Primary analysis will be on an intent-to-treat basis; per-protocol
analysis will be undertaken as secondary analysis. The primary outcome will be analysed using hierarchical mixed-
effects linear regression. Secondary outcomes will be analysed using mixed-effects linear regression, mixed-effects
logistic regression, and mixed-effects Poisson models for secondary outcomes depending on whether the outcome is
continuous, binary, or count data. A cost-effectiveness and cost-utility analysis will be undertaken.
Discussion: This definitive, national, multi-site trial is of sufficient size to evaluate MBT to inform policymakers, service
commissioners, clinicians, and service users about its potential to treat offenders with ASPD and the likely impact on
the population at risk.
Trial registration: ISRCTN 32309003. Registered on 8 April 2016.
Keywords: Antisocial personality disorder, Randomized controlled trial, Mentalization-based treatment, Probation,
Personality disorder, Offenders, Aggression, Violence, Patient and public involvement, Economic evaluation
Background
Personality disorder is substantially overrepresented in
offending populations. Multiple studies consistently
report a high prevalence of personality disorder in of-
fenders in general [1] and in individuals with convic-
tions for violent offences in particular [2]. Antisocial
personality disorder (ASPD) is the most common per-
sonality disorder in criminal justice settings [3, 4].
This disorder is characterized by a failure to conform
to social norms with respect to lawful behaviours; ir-
ritability and aggressiveness; impulsiveness; disregard
for the feelings and safety of others; and disregard for
one’s safety and for the consequences of one’s behav-
iour [5, 6]. The aim of this study is to establish if an
intervention targeting the spectrum of symptoms and
behaviours associated with ASPD is of value in im-
proving individual mental health and reducing associ-
ated public health and social burden.
ASPD is associated with high levels of comorbid
conditions [7–10]. Over 90% of individuals with
ASPD have at least one other psychiatric disorder
[11], at least 50% have co-occurring anxiety disorders
[12], and 25% have a depressive disorder [13]. Men
with ASPD are 3–5 times as likely to misuse alcohol
and illicit drugs as those without ASPD [14], and
women with ASPD have an even higher likelihood of
drug and alcohol misuse [14, 15]. ASPD is also asso-
ciated with physical disability [16] and premature
mortality [7]. Men with ASPD have a higher rate of
premature death than men of the same age without
the disorder, due not only to an increased risk of sui-
cide but also to reckless behaviours such as drug mis-
use and aggression [8].
The prevalence of ASPD has been reported as 0.6%
in the UK general population [5], although it may be
underdiagnosed in the community [17]. Nonetheless,
there is a wide disparity between the prevalence of
ASPD among the general population and among the
offending population: in the UK prison population,
just under two thirds of male remand prisoners, half
of male sentenced prisoners, and one third of female
prisoners meet diagnostic criteria for ASPD [4]. Al-
though the prevalence of ASPD in probation services
has not been fully explored, a screening study showed
that nearly half of those on probation had probable
personality disorder [18], an estimate likely to be
higher among those supervised as ‘high risk’. In
addition, reforms to the UK probation system in 2013
mean that ASPD is likely to be even more prevalent
in the high-risk population supervised under the Na-
tional Probation Service (NPS) in which the study is
being conducted.
The contribution of ASPD to violent criminal behav-
iour is clear: it is associated with a significantly increased
likelihood of committing violent crimes [19, 20] and is
highly predictive of future violence, future reconviction
or rapid re-incarceration upon release, and severity of
recidivism [21, 22]. The social impact of individuals
whose ASPD manifests in the form of violent criminal
behaviour includes direct physical and emotional harm
to victims, damage to property, use of police time, in-
volvement with the criminal justice system, and in-
creased use of healthcare facilities [23]. Finding an
effective treatment to reduce aggression in individuals
with ASPD has potential public health benefits, both dir-
ectly, by improving the health of those with ASPD, and
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indirectly, through reducing the adverse consequences
for victims, families, and communities.
Although the treatment of ASPD is a well-recognized
priority, many studies evaluating interventions for anti-
social behaviour have not looked at personality disorder
diagnoses, and no intervention has been established as the
treatment of choice for addressing the symptoms of
ASPD. The paucity of studies in this area is notable [24];
only a small number of high-quality trials of specific ther-
apies for ASPD have been conducted. We conducted a
systematic literature search under National Collaborating
Centre for Mental Health guidance, focusing on papers
published from 2009 to 2016 (since the UK National Insti-
tute for Health and Clinical Excellence (NICE) review [5]
was completed), using a strategy consisting of randomized
controlled trial (RCT) and systematic review filters com-
bined with subject heading and free-text phrases for
ASPD. The search strategy was run using the standard
mental health-related and allied health bibliographic data-
bases (PsycINFO, EMBASE, AMED, and MEDLINE—
using the Ovid interface). The search yielded 460 results
after deduplication. After excluding results that were not
journal papers (11), did not focus on ASPD (301), did not
focus on quantitative treatment outcomes for existing
ASPD (133), and did not differentiate ASPD from other
personality disorders (10), only five results remained: three
trials [25–27] and two Cochrane reviews [28, 29]. Of the
trials, only one study was conducted in a community sam-
ple [25]; this was not a definitive RCT but an exploratory
trial in a small sample of adult men with ASPD (N = 52),
which investigated the feasibility of carrying out a full
RCT of cognitive-behavioural therapy versus treatment as
usual. Four ongoing studies were also found by searching
trial registries. These trials’ sample sizes were relatively
small: one of N = 114, the others of N < 50. Moreover,
within their samples, these trials did not differentiate
ASPD from other disorders such as borderline personality
disorder (BPD) or paranoid personality disorder, or from
autism. The search also revealed a number of meta-
analyses, including a recent Cochrane review, which high-
light the lack of evidence to support the use of any inter-
vention for ASPD and urgently recommend that research
be carried out to determine effective and cost-effective in-
terventions [5, 28–31]. In this paper, we present the proto-
col for a large-scale RCT to generate new knowledge to
address this gap in existing knowledge.
We propose the randomized evaluation of a psycho-
therapeutic model, mentalization-based treatment
(MBT) for ASPD (MBT-ASPD). MBT is a manualized
intervention that is based on the assumption that indi-
vidual differences in the capacity to understand behav-
iour in terms of mental states arise as a result of
variability in the social environment in early childhood,
when mental state understanding of behaviour is
normally acquired [32–34]. MBT integrates cognitive
and relational components and provides a structured
therapeutic process during which the patient’s mind be-
comes the focus of treatment, centring on his/her cap-
acity to accurately interpret the meaning of actions in
terms of mental states (e.g. beliefs, thoughts, feelings, or
desires). People with ASPD show impaired recognition
of basic emotions [35], impaired capacity to link mental
states to behaviour [36, 37], and difficulty with
perspective-taking problems and in reading others’ men-
tal states [38–43]. They perform far worse than controls
on subtle tests of mentalizing [44, 45]. These observa-
tions are consistent with a number of theories of anti-
social behaviour [46, 47], including the deficit theory in
the mentalizing literature, as well as the mentalizing
model of antisocial behaviour, which is premised on the
dysfunction of the attachment system that then tempor-
arily inhibits affect regulation and mentalizing abilities
[48–51]. Antisocial behaviour and violence tend to occur
when an understanding of others’ mental states is devel-
opmentally compromised (fragile) and prone to being
lost when the attachment system is activated by
perceived threats to self-esteem, such as interpersonal
rejection or disrespect [52]. Normally, mentalizing (i.e.
envisioning the subjective state of the victim) prevents
interpersonal violence [53]; this means that individuals
with vulnerable mentalizing capacities can be behaviour-
ally volatile in moments of interpersonal stress. Support-
ing the capacity to identify others’ emotions and
intentions may not only assist social functioning but also
reduce the risk of antisocial behaviour. Indeed, mentaliz-
ing has been shown to be a protective factor against ag-
gression in people with violent traits [39]. Encouraging
mentalizing has been shown to reduce school violence
[54, 55], and MBT has demonstrated success in treating
symptoms of impulsivity in individuals with comorbid
BPD and ASPD [56]. Other studies of forensic patients
with personality disorder have found that participants’
views of the processes by which therapeutic changes
occurred tended to identify realizations that in turn
reflected improved mentalizing [57, 58].
Recognizing the therapeutic potential of MBT for
ASPD, the developers have adapted MBT specifically for
individuals with ASPD, in line with the NICE guideline
recommendation that interventions for ASPD should be
geared to enabling individuals to better examine their
own states of mind and understand others’ minds, and
to behave more prosocially [5]. MBT-ASPD is a complex
psychological intervention delivered using a combination
of group and individual sessions [53, 59–61], which aim
to enhance mentalizing by helping participants to de-
velop metacognitive understanding of their difficulties
with violence and achieve control over their aggression
by addressing relevant drivers such as interpersonal
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misattributions (by improving interpersonal understand-
ing through cognitive and affective identification with
the experiences of others) and emotion dysregulation
(by facilitating controlled and conscious mentalizing ra-
ther than automatic, non-reflective, non-conscious
mentalizing).
Aims
The primary aim of the Mentalization for Offending
Adult Males (MOAM) trial is to address the following
research question: is probation as usual (PAU) supple-
mented with MBT more effective and cost-effective than
standard PAU alone for reducing aggressive antisocial
behaviour in male offenders under community supervi-
sion who meet DSM-IV diagnostic criteria for ASPD? As
there is currently poor characterization of the primary
and secondary care needs of people with ASPD, the trial
will aim to investigate the impact of MBT on a range of
health-related and behavioural outcomes, some of which
are of interest irrespective of any diagnosis (e.g. quality
of life) and some of which are particularly pertinent to
ASPD and its symptoms (e.g. offending, violence, sub-
stance use, remission from categorically defined ASPD
status), and to examine the mediators and moderators of
these outcomes. The trial will also aim to establish the
relative cost-effectiveness of MBT and PAU, taking into
account costs incurred and the return on investment
across health services, social services, the criminal justice
sector, and voluntary sector services during the 24-
month period following randomization. Additionally, the
trial will aim to analyse offender referral information to
identify trends, calculate the size of the population likely
to benefit from an intervention for ASPD, map out-
comes from current interventions, and make recommen-
dations about treatment groupings and targeting of
services. Finally, the trial aims to generate and dissemin-
ate data that support policymakers, service commis-
sioners, and service providers in making evidence-based
decisions about planning and delivering services for of-
fenders with ASPD on probation and in improving the
management of mental health needs of offenders with
ASPD in the community.
Methods
Trial design
The MOAM trial is a pragmatic, multi-site RCT com-
paring MBT with PAU for adult males meeting DSM-IV
diagnostic criteria for ASPD [62], who are under com-
munity probation supervision. The design is a single-
blind (with researchers being blinded) RCT of a 1-year
programme of MBT-ASPD, which comprises weekly
group sessions (75 min) and monthly individual sessions
(50 min), compared with the usual services provided by
probation (i.e. PAU) for this client group. Typically,
PAU can include a variety of treatments, ranging from
those that directly address personality disorder (e.g.
schema-focused therapy) to those that address more spe-
cific criminological characteristics (e.g. anger manage-
ment programmes, substance misuse interventions,
domestic violence interventions), although in some ser-
vices there are no targeted treatment options currently
available for participants with a diagnosis of ASPD. This
trial is unique among studies evaluating interventions
for antisocial behaviour in that it is a full RCT with a
large sample size, which targets ASPD as the primary
diagnosis, and which differentiates ASPD from other
mental health conditions.
Ethics
The study protocol was approved by the London –
South East Research Ethics Committee (reference num-
ber 14/LO/1696) and the National Offender Manage-
ment Service (reference number 2014-315). Research
and development approval has been sought and obtained
for each trial site by the relevant NHS Trust and NPS
lead in each geographical area. The trial sponsor, Uni-
versity College London, played no part in study design;
collection, management, analysis, and interpretation of
data; writing of the report; and the decision to submit
the report for publication.
Study setting
This study involves two UK statutory services—the NPS
in partnership with NHS Trusts—at 13 sites. The MBT
clinical services, like other National Offender Personality
Disorder community services, were designed to be deliv-
ered through existing community partnerships between
Probation Trusts and health service providers. Sites in
England and Wales were invited to bid for the clinical ser-
vices in 2014, prior to the commencement of the RCT in
2016. The National Offender Personality Disorder
Programme covers England and Wales, but not Scotland
or Northern Ireland, hence the restriction of sites to Eng-
land and Wales. Providers needed to already be part of the
Offender Personality Disorder Pathway Strategy with an
existing contract in place between NHS England and the
Probation Trust to deliver the community service specifi-
cation in addition to a subcontract with a health service
provider. Services were also selected on the basis of (a)
geographical spread across England and Wales, (b) demo-
graphic representativeness (urban vs rural), and (c) avail-
ability of participants for recruitment into the trial
(favouring somewhat larger services). The 13 sites com-
prise the following: NPS London and the Tavistock and
Portman NHS Foundation Trust in conjunction with Bar-
net, Enfield, and Haringey Mental Health NHS Trust;
NPS London and the South London and Maudsley NHS
Trust; NPS Lincolnshire and the Lincolnshire Partnership
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NHS Foundation Trust; NPS Merseyside and the Mersey-
side Care NHS Trust; NPS Devon & Cornwall and the
Devon Partnership NHS Trust; NPS London and the East
London NHS Foundation Trust; NPS London and the
Oxleas NHS Foundation Trust; NPS Lancashire and the
Lancashire Care NHS Foundation Trust; NPS Stafford-
shire and West Midlands and the South Staffordshire and
Shropshire Healthcare NHS Foundation Trust; NPS Not-
tinghamshire and the Nottingham Healthcare NHS Foun-
dation Trust; NPS Gloucestershire and the Avon and
Wiltshire Mental Health Partnership NHS Trust; NPS
Wales and Hywel Dda University Health Board; and NPS
West Yorkshire and Leeds & York Partnership NHS
Foundation Trust.
Participants
A total of 302 participants will be recruited, with ap-
proximately half of the consecutive qualifying cases be-
ing randomized to MBT and the other half to PAU. The
unit of randomization is the individual participant.
Participants will be identified from a pool of offenders
subject to statutory supervision by the NPS and assessed
as having indications of personality disorder according
to the Community Personality Disorder Pathways Ser-
vice Specification of the Offender Personality Disorder
Pathway Strategy following case identification, consult-
ation, and formulation.
Eligibility criteria
Inclusion and exclusion criteria have been carefully se-
lected on the basis of previous research and clinical ex-
perience to provide an appropriate balance between
homogeneity (to ensure that the treatment under inves-
tigation is appropriately aimed toward the diagnostic
needs profiles of those within the trial) and heterogen-
eity (to accurately reflect the mix of antisocial offenders
under the management of community probation and to
ensure that the results of the trial are generalizable to
the wider population of people diagnosed with ASPD)
within the sample, as well as to enable comparability
with other trials investigating the treatment of aggres-
sion and of antisocial behaviour [25, 63–65].
All participants will meet the following inclusion
criteria:
 Male and aged 21 years or over
 Subject to statutory supervision by the NPS
 At least 6 months remaining of their licence or
community sentence
 Fulfilling DSM-IV diagnostic criteria for ASPD
(assessed by the Structured Clinical Interview for
DSM-IV (SCID) Axis II Disorders (SCID-II)) [66]
 Score of at least 15 on the Overt Aggression Scale –
Modified (OAS-M) [67]
 Adequate English language and cognitive capacities
to participate in informed consent and group
therapy.
The exclusion criteria applied will be minimal and are
as follows:
 Serving a conviction for child sexual offences
 Primary diagnosis of a psychotic disorder or
neurodevelopmental disorder.
Sample size and power calculation
The sample size (N = 302) has been chosen to have
90% power, at a two-sided 5% significance level, to
detect a significant difference between groups when
the change in OAS-M score is on average 10 points
less in the MBT arm (with a standard deviation of
20) at the primary endpoint 24 months after
randomization. Hollander et al. [68] reported the
pooled standard deviation of the change in OAS-M
score from baseline to 10-week follow-up as being
just over 9 for the pharmaceutical intervention
assessed in that study. Due to the longer follow-up
period of the present trial and the non-
pharmaceutical nature of the planned intervention, we
have chosen to increase the standard deviation used
in our power calculation to 20. To take into account
potential clustering by clinician in the MBT arm, we
assume the intraclass correlation coefficient to be
0.05. In this case, using established methods to take
account of clustering [69], 95 participants per arm will
give 90% power. We anticipate attrition and dropout
to be 37%, based on several sources including our
own preliminary work and several larger data sources
(a meta-analysis of attrition rate in offender treatment
literature [70], a systematic review of non-completion
of treatment for personality disorder [71], and an em-
pirical evaluation of treatment disengagement in of-
fenders with personality disorder [72]). To account
for this loss, initial recruitment of 151 participants
per arm is anticipated to result in 95 participants
remaining per arm after attrition and dropout. Our
target sample size is therefore 302 participants, which
will give sufficient power to detect a medium effect
size of 0.5 change in participants’ OAS-M score.
Demographic and clinical details from those refusing
randomization will be retained to explore whether the
trial population is representative. To assess treatment
acceptability, we will compute the proportion of referred
individuals who never attended, the number of sessions
attended, and the number who drop out of treatment or
request to be referred to other treatments. All partici-
pants who do not formally withdraw from the study will
be followed up on routine measures of outcome.
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Peer researchers
A crucial aspect of this trial design is the use of peer re-
searchers. This approach enables individuals with similar
key criteria to the participant group to play an active
role in the research process, by taking on the role of re-
searchers. There are a number of potential benefits asso-
ciated with using peer researchers, including the
increased likelihood of accessing people and topics that
traditional research and service staff may not be able to
reach [73] and the potential to enhance the accuracy
and validity of participant data through peer researchers
being better placed to put participants at ease, thus
stimulating free discussion and more open dialogue [74].
Peer researchers may also reduce the power differentials
between researchers and participants, thereby facilitating
trust and rapport and promoting honest disclosure of
sensitive information [75]; this is particularly important
in our target population, given that those involved in the
criminal justice system often have an entrenched distrust
of authority. In this study, peer researchers with lived
experience of the criminal justice system, provided by
the charity User Voice, will work alongside traditional
research assistants under robust supervision arrange-
ments to conduct baseline and outcome assessments.
Peer researchers will be expected to have successfully
reintegrated into society and have prior experience of an
engagement role.
Recruitment and baseline procedures
Figure 1 shows the expected flow of participants from
recruitment through to the end of the study, based on
observed screening and referral data to date. In addition
to aspects that apply to recruitment for any trial (e.g. the
clear application of eligibility criteria, a standard proced-
ure for obtaining informed consent), recruitment for this
trial will be especially sensitive to the community proba-
tion context and will be based on effective partnerships
with referral agencies and strong relationships with the
participants. Consequently, the trial team has developed
strong collaborative relationships with the MBT team at
each site to achieve the high levels of accrual necessary
to ensure sample comparability and reasonable
generalizability.
We have developed a multiple gating procedure for re-
cruitment. Decisions about eligibility for the trial will be
made at three key points: (1) by the referring agencies
(i.e. individual Offender Managers across each site) fol-
lowing a discussion with the Specialist Offender Man-
ager (SOM) in the MBT team to identify ostensibly
suitable potential participants; (2) through an explana-
tory meeting between the offender, the MBT team, and
the research team following the initial referral, to explain
the research trial, invite participation, and answer any
questions about the clinical services potentially available
to the participant; (3) as a result of discussions between
the MBT clinicians, Assistant Psychologist, and Research
Manager following an in-depth clinical assessment and
formal diagnostic evaluation, to screen out offenders
who do not meet the eligibility criteria.
Experience suggests that each of these screens tends to
reveal different criteria for ineligibility, and their use in
combination minimizes the (considerable) effort of re-
cruitment. For example, the SOM tends to identify and
screen out cases whose offending history includes child
sex offences, whereas discussions between the MBT and
research teams and the potential participant most com-
monly identify and screen out individuals who are insuf-
ficiently motivated to engage with group treatment. The
clinical assessment reveals offenders who are ineligible
due to their lack of suitability for tolerating a group set-
ting or psychotherapeutic treatment in general, and the
formal diagnostic evaluation is necessary to confirm the
individual’s psychiatric diagnosis.
Screen 1
The SOMs in the MBT teams will work across each of
the 13 sites, taking referrals from Offender Managers
who will put forward individuals they deem agreeable to
being approached about participation and who have ad-
equate English and cognitive capacities to participate in
informed consent and group therapy. SOMs will be
available to discuss cases that potentially meet the eligi-
bility criteria for MBT. In addition, the SOM and Assist-
ant Psychologist at each site can directly screen for
suitable cases by reviewing their caseload against the in-
clusion and exclusion criteria, before approaching the
respective Offender Manager to make a referral.
The decisions made by the SOM constitute the first
screen. A standard referral form for each locality is used
in liaison with the research team, including specific in-
formation pertaining to inclusion and exclusion criteria.
Screen 2
Following acceptance of the referral by the MBT team, a
meeting will be arranged between the MBT and research
teams and the offender, to inform the offender about the
trial and the opportunity to participate. The discussions
at this meeting include what the MBT intervention
would entail and the alternative PAU path (the best
available alternative treatment at that locality; see below)
should the offender not be randomized to receive MBT.
Offenders will be provided with participant information
sheets that have been co-designed with input from ex-
offenders to make them as useful and accessible as pos-
sible. Offenders will be given a minimum of 24 h to con-
sider participation.
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Screen 3
If the offender decides to participate following the ex-
planatory meeting, an in-depth clinical assessment and
formal diagnostic evaluation will be arranged. MBT cli-
nicians will conduct history-taking, administering the
SCID-II psychosis screen, and ascertaining the offender’s
ability to engage in psychotherapeutic treatment and tol-
erate a group setting.
Consent forms will be signed by both the offender and
the site’s lead MBT clinician, who will assess the of-
fender’s capacity to provide informed consent. Consent-
ing to the trial includes providing permission to access
police records, remaining in effect for 2 years, and health
records, remaining in effect for 5 years.
The site’s Assistant Psychologist will administer the
SCID-II screen and the OAS-M. If all of the inclusion
Fig. 1 Expected flow of participants from recruitment through to the end of the study
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criteria and none of the exclusion criteria are met, the
participant will progress to the next stage of the research
process to complete the baseline measures.
Baseline measures
For offenders who sign the consent forms, the researcher
will administer pre-randomization questionnaires and
measures to be completed during this contact (i.e. before
group assignment). When all the instruments have been
completed and eligibility for the trial has been con-
firmed, randomization will be performed and details
communicated to the referrer, MBT team, and partici-
pant within 48 h.
Randomization and procedures to minimize bias
Following consent and baseline measures, a trial identifi-
cation number will be assigned to eligible consenting
participants and a recruitment ‘dam’ created behind
which a participant pool will be built up, from which
participants will be randomized to enable MBT groups
to start. Once groups have started, sequential assignment
will allocate participants to MBT or PAU in a 1:1 ratio.
Randomization will be undertaken off-site, using a dy-
namic adaptive allocation algorithm [76] accessed by a
secure web portal to the system held at NWORTH Clin-
ical Trials Unit (CTU) and maintained by a statistician
independent of the analysis and research teams to en-
sure blinding. Stratification will be by site, age (21–25;
26–39; 40+ years), probation order type (Community
Sentence; On Licence Post-Prison), and time remaining
on probation (less than 12months; 12 months and over).
Treatment site is included in the minimization stratifica-
tion to control for differences between sites. To
minimize bias that could arise from knowledge of treat-
ment allocation, researchers will be blind to participants’
treatment. The allocation to treatment arms will not be
modified unless the local principal investigator, with the
agreement of the clinical supervisor or the Trial Steering
Committee (TSC), identifies severe risks of adverse
events (homicide, suicide, serious injury, etc.) associated
with the experimental treatment. Experimental treat-
ment will be discontinued if the participant breaks the
conditions of probation and is asked to serve the re-
mainder of their prison sentence for a time which pre-
vents any further attendance or if the participant
commits further offences and receives a custodial sen-
tence for the fresh conviction that is longer than the
remaining time of treatment.
Planned interventions
Implementing standard PAU or PAU supplemented with
MBT will not require alteration to usual pathways (in-
cluding use of any medication), and these will continue
for both trial arms.
PAU
Participants randomized to receive PAU will remain
under the supervision of the NPS for the duration of
their licence or community sentence. PAU is a well-
specified and stringently monitored standard procedure
used in the management of offenders under community
supervision. It consists of regular contact with a desig-
nated Offender Manager for the duration of the of-
fender’s licence or sentence, and includes referral for
additional interventions as indicated in Ministry of Just-
ice guidance. PAU participants will be free to be referred
by their Offender Manager for any locally available treat-
ment (except MBT) designed to reduce reoffending (e.g.
anger management programmes, substance misuse inter-
ventions). Provision of these interventions is not uniform
across the UK but dependent on local availability; in
some areas, there may be no targeted interventions avail-
able. Unlike MBT, none of the interventions that partici-
pants may receive under PAU involve targeting the
capacity to envision mental states more accurately.
Details of services accessed under PAU will be docu-
mented by the SOM to facilitate economic data collec-
tion and evaluation. Additional site-specific strategies
(e.g. separate supervision groups) will ensure that MBT
principles and practice do not directly influence the
management of participants randomized to PAU. PAU
will last for 12 months, after which participants who still
have time remaining on their licence or community sen-
tence will remain under the supervision of the NPS for
the duration. Participants whose licence expires during
the trial period may remain under the NPS on a volun-
tary basis to complete the 12-month period.
PAU supplemented with MBT-ASPD
The treatment intervention is a 1-year programme of
group and individual sessions of MBT-ASPD. Partici-
pants randomized to MBT-ASPD receive weekly group
therapy for 75 min and monthly individual therapy for
50 min. Each MBT-ASPD group is run by two trained
MBT clinicians and contains a maximum of eight partic-
ipants, using an ‘open’ rolling entry group, with new par-
ticipants joining as others leave. The group process
enables participants to challenge each other about their
understanding of current self-identified critical interper-
sonal experiences and focuses particularly on elaborating
the mental state background of interactions character-
ized by conflict that might normally trigger aggression.
The content of the group therapy sessions is steered by
the clinicians toward encouraging the participants to talk
about their mental states related to recent violent inci-
dents by linking their actions to a broader range of their
current subjective and emotional experience (i.e. to
‘mentalize’ them). A monthly 50-min individual session
provides an opportunity for participants to address
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personal issues that have occurred in the group. Many
participants find it more difficult to talk in front of other
members of the group about the relationship difficulties
they experience in their external lives, and may use the
individual sessions to do this too. Both group and indi-
vidual sessions focus on identifying thoughts and feel-
ings associated with aggressive impulses, with particular
emphasis on understanding emotional cues, recognizing
emotions in oneself and others, understanding others’
experiences in relation to one’s own, and clarifying
threats of loss to mentalizing in the context of life expe-
riences, both currently and historically.
All participants randomized to this arm of the study
have an allocated clinician. Staff providing MBT ses-
sions are chartered health professionals with a core
clinical training background (e.g. clinical psychology,
nursing, medicine) who have undergone an MBT
training course. Where possible, recently trained clini-
cians are paired with an experienced clinician to pro-
vide group MBT.
The evaluation of the adequacy of protocol delivery
and adherence to the model will include treatment in-
tegrity measures based on the MBT Adherence and
Competence Scale [77], applied to video recordings of
a random sample of sessions. This instrument enables
coders to rate therapist activity and appropriateness
in five key domains of MBT with ratings on Likert
scales supported with anchored descriptors. As clini-
cians will be specially trained for the trial, it is critical
to separately evaluate both clinician adherence and
level of clinician competence, which will be based on
the independent rating of randomly selected session
recordings. The scale measures both the frequency of
therapists’ actions (adherence) and the quality of the
delivery of those actions (competence). Adherence re-
fers to the number of items used within a domain
and their frequency of use; quality refers to the clini-
cian’s demonstration of how the interventions are de-
livered in terms of (a) expertise, competence, and
commitment; (b) timing; (c) taking account of the
context and content of the session; (d) matching the
mentalizing state of the patient; (e) responding to
where the patient appears to be; and (f) an extensive-
ness component in terms of items used when working
in the domain. A definition of skill/quality is given
for each domain.
Clinicians with average scores above 3.5 will be
considered to have achieved acceptable levels of
adherence and competence. Adherence will be moni-
tored on a monthly basis through clinical supervision
sessions using the MBT Adherence and Competence
Scale, based on independent rating of randomly se-
lected session video recordings, to ensure that clinical
staff are consistently on-model.
Assessments and outcome measures
To maximize the validity of the outcome evaluations, as-
sessments will be made across multiple domains using
multiple methods and sources.
Primary outcome
The primary outcome is the frequency of aggressive
antisocial behaviour as measured by an adapted version
of the OAS-M and is collected every 3 months. The
OAS-M provides information to establish frequencies of
verbal aggression and physical aggression against objects,
against others, and against the self. The OAS-M is a ro-
bust semi-structured interview and is the most widely
used measure of aggression in trials and clinical studies
in this area. It has been used with many different out-
patient populations, including those with Cluster B per-
sonality disorders. It is one of the only measures of
aggression that assesses actual aggressive behaviour, and
its format offers several advantages over most available
instruments for assessing anger and aggression, includ-
ing allowing the probing of vague and inconsistent an-
swers [67]. It is therefore well suited to accurate
evaluation of aggressive behaviour and of change over
time, both as a research instrument and as a comple-
ment to many of the current self-report measures. In
agreement with the developer of the measure, the OAS-
M, adapted for the current study, uses a weighted scale
taking the number of reported endorsed items and
multiplies them in accordance with the severity of each
item. Aggression is the primary outcome in this study as
it is the key characteristic of ASPD, the primary driver
of interpersonal violence, and a key contributor to health
status [78, 79]. The primary endpoint is at 24 months
post-randomization. As a secondary outcome, the
adapted OAS-M is collected at other time points (3, 6, 9,
15, and 18months).
Secondary outcomes
The domains that the investigators consider key to the
intervention are violence, anger, offending behaviour,
impulsivity, alcohol and substance misuse, self-harm and
suicidality, general health and wellbeing, service satisfac-
tion and engagement outcomes, and remission in ASPD
diagnostic status. These secondary outcomes will be
assessed by using objective and self-report measures. Es-
timates of the population at risk resource use data rele-
vant to conducting a comprehensive economic
evaluation will be collected alongside these outcomes, as
well as data on variables associated with putative mecha-
nisms of change.
Objective measures
Objective outcomes of health service use will be col-
lected from record linkage using participants’ NHS
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numbers at 6-monthly intervals during the intervention
and the follow-up period until the 24-month follow-up
point.
Objective outcomes of offending behaviour, including
withdrawal of licence, arrests, and reconvictions, will be
collected from police computer records at 6-monthly in-
tervals, for the 6 months before randomization and dur-
ing the intervention and follow-up period until the 24-
month follow-up point. The number of records of
offending behaviour (count data) will be obtained, and
6-month periods free of any offending behaviour will
also be recorded (binary data). Data will be obtained
from participants’ records on nDelius (the national pub-
lic sector offender case-management system) and the
Police National Computer database; these records detail
information on breaches of licence conditions, police
contacts, charges, court appearances, criminal orders, ar-
rest rates, and frequency, severity, and type (violent/non-
violent) of offending behaviour.
These objective outcomes of health service use and
offending behaviour will be available regardless of loss to
follow-up; this will allow the use of multiple imputation
techniques. If loss to follow-up is considerably different
between arms and the primary outcome is significant,
we will perform a sensitivity analysis to the impact of
missing data not being missing at random, as described
by White et al. [80].
Self-report measures
Researchers will administer pre-testing questionnaires
during the initial contact with participants after they
have given consent to participate in the trial, before
group assignment (as described above). Follow-up as-
sessments will be made at 3-month intervals for the pri-
mary outcome measure and for secondary outcome
measures assessing violence, intimate partner violence,
and anger; at 12-month intervals for the secondary out-
come measures assessing categorically defined ASPD
and rates of desistance; and at 6-month intervals for all
other secondary outcome measures. Assessments will
continue for the duration of the 12-month treatment
and for 12 months post-treatment. Self-report measures
of violence, offending behaviour, substance misuse, self-
harm, and suicidality, as well as general health and well-
being, service satisfaction, and engagement, will be
collected.
Violence will be measured by the MacArthur Commu-
nity Violence Screening Instrument [25, 81]. This meas-
ure assesses the presence, severity, and frequency of
violent behaviours and is one of the few instruments
available to differentiate between general aggression and
specific interpersonal violence [82].
Intimate partner violence will be measured by the
Short Form of the Revised Conflict Tactics Scales. This
measure includes scales to measure physical assault, psy-
chological aggression, and sexual coercion against a
partner in a dating or marital relationship.
Anger will be measured by the State-Trait Anger Ex-
pression Inventory-2 (STAXI-2) [83, 84]. The STAXI-2
is a psychometrically robust questionnaire [85] designed
to assess the experience, expression, and control of
anger, which commonly drives aggression.
Alcohol use, which has been strongly associated with
aggression and offending [86], will be measured by the
Alcohol Use Disorders Identification Test (AUDIT) [85,
87]. The AUDIT is widely used as an alcohol use screen-
ing measure. It assesses three aspects of drinking: quan-
tity and frequency, indicators of dependence, and
adverse consequences suggesting harmful use.
Drug use, which is similarly linked to aggression and
offending [88], will be measured by the Drug Use Disor-
ders Identification Test (DUDIT) [89], which assesses
frequency of use, indicators of dependence, and adverse
consequences suggesting harmful use. The DUDIT has
several advantages over other instruments, including a
brief administration time (5 min) and its focus on recent
use and consequences.
Self-harming behaviours, an indicator of impulsivity
and a target of MBT, will be measured by the Self-Harm
Inventory [90], a widely used measure that yields a se-
verity of self-harm score based on the frequency of a
wide range of impulsive behaviours.
Suicidal behaviour, a further complication of offending
behaviour with ASPD [91], will be measured by the
Suicidal Behaviours Questionnaire-Revised [92]. This in-
strument assesses four different dimensions of suicidal-
ity, including frequency of suicidal ideation and threat of
suicide attempt.
Health-related quality of life will be measured by the
EQ-5D-5L [93, 94]. The EQ-5D-5L is a standardized in-
strument for use as a measure of health outcome that is
applicable to a wide range of health conditions and
treatments. In this study, it will be used to provide a
generic measure of health for both clinical and economic
appraisal.
Mental health status will be measured by the Symp-
tom Checklist-90 – Revised (SCL-90-R) [95]. The SCL-
90-R assesses psychological distress in terms of nine pri-
mary symptom dimensions, including depression, anx-
iety, hostility, and paranoid ideation—all potential
drivers of aggression.
Personality dysfunction will be measured by the Per-
sonality Inventory for DSM-5 – Brief Form (PID-5-BF)
[96]. This 25-item personality trait assessment scale as-
sesses negative affect, detachment, antagonism, disinhib-
ition, and psychoticism and will provide a means of
assessing change in the trait domains that are most
prominent in ASPD.
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Categorically defined ASPD will be measured by the
ASPD module of the SCID-II, to assess whether MBT
produces remission in ASPD diagnostic status.
Mentalizing capacity will be evaluated by the 16-item
Brief Reflective Functioning Questionnaire [97] to assess
whether MBT’s proposed mechanism of change is in line
with any symptomatic improvements.
Rates of desistance will be measured by the Redemp-
tion and Condemnation Self-Narrative Scale version 2 to
assess whether MBT increases rates of desistance in the
participants.
Clinician-rated measures
Clinicians (therapists, Assistant Psychologists, and Of-
fender Managers) will use the Service Engagement Scale
[98] to determine the level of engagement of partici-
pants, as rated on four subscales: availability, collabor-
ation, help-seeking, and treatment adherence.
Economic evaluation
Health economic analysis will be conducted by King’s
Health Economics at the Institute of Psychiatry, Psych-
ology and Neuroscience, King’s College London, and will
explore the relative costs and cost-effectiveness of
MBT+PAU versus PAU. Although there is a preference
for economic evaluations carried out on NHS services to
take an NHS and personal and social services cost per-
spective, as recommended by NICE [99], in this case our
primary analysis will take a wider societal perspective,
including all healthcare, social and personal services, vol-
untary sector services, costs to the criminal justice sec-
tor, including probation, and the costs resulting from
any crimes committed. The wider perspective is relevant
and valid here because the interventions being compared
are delivered in a criminal justice setting and the hy-
pothesized impact will fall across both healthcare and
criminal justice. A secondary analysis will consider the
NHS/personal and social services costs only. Data on
MBT contacts will be collected directly from sites, to
avoid participants revealing their group allocation to the
researchers. Data on the use of all other services, includ-
ing PAU, will be collected in interviews using the Secure
Facilities Service Use Schedule [100]. This instrument
has been adapted to the current study population to en-
sure comprehensive coverage and face validity. Informa-
tion on criminal activity will be extracted from police
records. The cost of the trial interventions will be calcu-
lated through a detailed micro-costing (or bottom-up)
approach using standard costing methodology [101],
which will involve estimation of the indirect time spent
on individual cases, including preparation, meetings,
telephone calls, and supervision, as well as detailed re-
cording of direct face-to-face contact. Other unit costs
will be sourced from routine sources for the unit cost
year 2017–2018 [102–104].
Follow-up assessment
Follow-up assessments will be conducted at 3-month in-
tervals for 24 months post-randomization. Primary out-
come measures will be collected every 3 months and
secondary outcome measures every 6 months. Table 1
shows a detailed outline of the planned measures at each
follow-up point throughout the trial.
Data management
Collection
Outcome measures data will be recorded using the Pa-
tient Owned Database (POD), an internet-based high-
security data collection and management software. The
use of POD automatically scores and transmits the data
to the data-analytic site without human interference re-
ducing the risk of data entry error. Once entered, the
data will be exported and cleaned by the CTU ready for
analysis by the trial statistician. In line with a data shar-
ing agreement with the NPS and UCL Data Protection
Policy, participants’ personal data will be collected and
securely stored in password-protected files only access-
ible by members of the research team during the course
of the study. At the end of the trial, all data will be ar-
chived in a safe and secure off-site location.
Auditing
The quality of data will be routinely monitored by the
Research Manager throughout the duration of the trial.
In addition, data quality will be monitored quarterly by
an independent audit group, which will be responsible
for reviewing data collection and completeness rates.
Statistical analysis
All planned statistical analyses will be specified in a Stat-
istical Analysis Plan that is agreed prior to unblinded in-
formation being made available to the trial statistician.
Primary analyses will be on an intent-to-treat basis, with
per-protocol (all participants who were randomized,
who met inclusion/exclusion criteria, and who attended
at least 35% of planned meetings with their parole offi-
cer) analyses undertaken as secondary. The characteris-
tics of the treatment groups will be described at
baseline. Preliminary analysis will investigate the pattern
of missing follow-up data.
Primary outcome
The primary outcome (OAS-M) at the various follow-up
times will be analysed using a hierarchical mixed-effects
linear regression with baseline OAS-M, length of sentence
for index offence, and the stratification factors used in the
randomization (except for site) as fixed effects. Patient ID
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and site will be included as random effects. A treatment
effect parameter for each follow-up time will be included,
although the primary one of interest will be treatment ef-
fect at 24months. Two-sided p values less than 0.05 will
be classed as significant.
Secondary outcomes
For the secondary outcomes, we will use mixed-effects
linear regression for continuous outcomes, mixed-effects
logistic regression models for binary outcomes, and
mixed-effects Poisson models for count data such as
number of offences. Missing outcome data due to
dropout will be accounted for by the mixed-effects
model under a missing-at-random assumption; missing
covariates will be accounted for using multiple
imputation.
Moderators of outcomes
The trial will evaluate the following as potential modera-
tors for the primary and any secondary outcomes that
are significantly different between arms: age, type of pro-
bation, length of probation, anxiety measured by the
SCL-90-R, Axis II comorbidities measured by the SCID,
p factor scores derived from a bi-factor analysis of the










MBT x x x x x
PAU x x x x x
ASSESSMENTS
Questionnaires—participant
Overt Aggression Scale – Modified x x x x x x x x x
EQ-5D-5L x x x x x
Symptom Checklist-90–Revised Short Form x x x x x
Alcohol Use Disorders Identification Test x x x x x
Drug Use Disorders Identification Test x x x x x
State-Trait Anger Expression Inventory x x x x x x x x x
MacArthur Community Violence Screening Instrument x x x x x x x x x
Short Form of the Revised Conflict Tactics Scales x x x x x x x x x
Self-Harm Inventory x x x x x
Suicidal Behaviours Questionnaire – Revised x x x x x
Secure Facilities Service Use Schedule x x x x x
Personality Inventory for DSM-5-Brief Form x x x x x
SCID-II, ASPD Module x x x
Brief Reflective Functioning Questionnaire x x x x x
Redemption and Condemnation Self-Narrative Scale version 2 x x
Questionnaires—clinician
Service Engagement Scale x x x x
National Probation Resources, Evaluation and System Schedule x x x x
Police and health data
Police records x x x x x
Health records x x x x x
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self-report outcome measures, baseline alcohol use mea-
sured by the AUDIT, and baseline drug use measured by
the DUDIT.
Moderators will be tested by including interaction pa-
rameters in the model and testing them for significance.
Mediators of outcomes
We will test the following as mediators (if there is a sig-
nificant difference between arms in the mediating vari-
able): alcohol use (AUDIT score); drug use (DUDIT
score); mood (scores on the anxiety and depression sub-
scales of the SCL-90-R); mentalizing (Brief Reflective
Functioning Questionnaire score).
We will also test the proportion of MBT planned ses-
sions attended as a post-baseline effect modifier (as it is
only collected in the MBT arm).
Economic evaluation
Mean total costs for the two groups at 24-month follow-
up will be compared using a regression model with base-
line costs as a covariate, an approach used despite the
likely skewed distribution of the data because of the im-
portance of the arithmetic mean in using the results for
policymaking [105]. To test the robustness of the nor-
mality assumption, bootstrapped confidence intervals for
the regression model will be also be calculated [106].
Quality-adjusted life years (QALYs) will be calculated
from EQ-5D-5L health status using UK values for utility
status [107] and assuming a linear change in utility over
time. A cost-utility analysis will combine costs with the
QALYs, a cost-effectiveness analysis will combine costs
with aggressive behaviour and incremental cost-
effectiveness ratios, and cost-effectiveness acceptability
curves will be generated. Sensitivity analyses will include
a test of the impact of the intervention costs on the
cost-effectiveness results, and the impact of missing data,
tested using multiple imputation of missing cost items.
Oversight and monitoring
Oversight committees
The study will be overseen by two oversight committees:
the TSC and a Data Monitoring and Ethics Committee
(DMEC). The TSC will be chaired by an independent
expert and will be responsible for monitoring progress
of the study and reviewing amendments to the trial
protocol. Committee members will include experienced
clinicians, commissioners of forensic mental health ser-
vices, criminal justice professionals, and service user rep-
resentatives. A group of clinicians with relevant
experience in the area and expert trial statisticians will
form the independent DMEC, which will be responsible
for monitoring recruitment and follow-up rates across
both arms of the trial, as well as serious adverse events
(SAEs) and ethical concerns. Minutes from the DMEC
will be shared with the TSC chair following each meet-
ing, and the TSC will report directly to the funder.
Adverse events
For this study, adverse events will be defined as immedi-
ate risk of harm to the participant or another person
and will be collected after the participant has provided
consent and enrolled in the study. Each event will be
logged by the research team following contact with the
participant and regularly reviewed by the Research Man-
ager, Clinical Lead, and Chief Investigator. If an adverse
event meets the criteria for a SAE between study enrol-
ment and the 24-month data collection time point, the
event will be logged and reported to the DMEC for re-
view. SAEs occurring after a participant is discontinued
from the study will not be reported unless the investiga-
tors feel that the event may have been caused by a study
protocol procedure.
Dissemination policy
The results of the study will be disseminated through
publications in peer-reviewed journals as well as presen-
tations, newsletters, and articles for the probation and
prison system and third sector organizations working
within the criminal justice system.
Discussion
This study will address key gaps in the offending and
health literature. To date, there have been very few high-
quality trials with a sufficiently powered sample size that
have evaluated therapeutic interventions for offenders
with a primary diagnosis of ASPD. The MOAM trial is
the first large-scale trial of treatment for offenders with
ASPD in the community and has a number of strengths
compared with other trials of interventions for antisocial
behaviour. First, it is a definitive RCT, conducted in
real-life community settings, at multiple sites with a rep-
resentative geographical spread and a range of clinicians
from diverse disciplinary backgrounds. Second, the sam-
ple size is sufficient to yield 90% power, even after ac-
counting for a potentially high attrition rate. Third, its
sample is selected on the primary diagnosis of ASPD as
fully differentiated from other mental health conditions.
Fourth, the trial design incorporates the innovative use
of peer researchers as a strategy to enhance the accuracy
and validity of participant data. Finally, the measures
employed will enable us to look beyond recidivism and
will capture the effects of MBT on a wide range of sec-
ondary health and behavioural outcomes, including diag-
nostic change of ASPD itself.
Aggressive antisocial behaviour has been chosen as the
primary outcome for this trial, in light of it being a core
feature of ASPD, an indicator of emotional wellbeing,
and a frequent cause of grounds for arrest. A range of
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secondary outcomes have also been chosen in order to
evaluate MBT’s possible impact on the wide range of
symptomatology and health outcomes experienced by
individuals with ASPD, including impulsivity, offending
behaviour, alcohol and substance misuse, self-harm and
suicidality, and general health and wellbeing. The
MOAM trial will also provide accurate information
about the services accessed under PAU. A comprehen-
sive cost-effectiveness evaluation will be undertaken to
examine both costs offset and costs saved in relation to
having received MBT or PAU. Thus, the trial will pro-
vide unprecedented data not only on the clinical effect-
iveness and cost-effectiveness of MBT-ASPD, but also
on the clinical effectiveness and cost-effectiveness of the
usual services available to this group while on probation.
Furthermore, the trial will analyse offender referral in-
formation to identify trends, calculate the size of the
population likely to benefit from an intervention for
ASPD, and make recommendations about treatment
groupings and targeting of services.
Information to date suggests that the trial protocol de-
tailed above is acceptable to all the sites and that recruit-
ment, data collection, and training are feasible in all
locations. Preliminary data on participant engagement
indicate that, of participants randomized to MBT, an
average of 55–65% attend group MBT sessions. Prelim-
inary data indicate that one third of participants drop
out at some point following randomization, entirely con-
sistent with attrition rates reported in other studies in-
volving treatment for offenders and patients with
personality disorders [70–72]. For participants who drop
out, the average length of engagement with the trial is
3–6 months; the most common reasons for dropout thus
far are lack of motivation (58%), recall to prison (35%)
and clinicians’ discretion due to repeated non-
attendance of MBT sessions (7%).
The authors acknowledge that there is such a scarcity
of evidence for effective interventions for ASPD that
additional trials are greatly needed. Beyond the comple-
tion of the MOAM trial, the authors recommend further
high-quality RCTs incorporating the following adapta-
tions: minimal involvement of the intervention devel-
opers, to minimize bias; a female sample, to improve
generalizability of results; longer-term follow-up, to de-
termine whether differential effects are maintained; and
investigation of the impact of differences in clinicians’
training, experience, and supervision, to determine min-
imal training and supervisory standards and compe-
tences for effective delivery of treatment.
Trial status
The trial is in its fifth year. Sites were launched in four
phases between January and September 2016, and recruit-
ment ended in August 2018. Treatment and follow-up
data collection are currently in progress. The protocol
paper was submitted after the end of recruitment as the
primary outcome, frequency of aggressive antisocial be-
haviour, is measured at the last follow-up meeting 24
months post-randomization. Outcome data will be avail-
able 24months post-randomization of the last participant.
Trial protocol version: v6.0, 2 December 2018.
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